Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

TitleTenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
Publication TypePublication
Year of Publication2019
AuthorsKim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW
Corporate AuthorsAdolescent Medicine Trials Network for HIV/AIDS Interventions
JournalAIDS Res Hum Retroviruses
Volume35
Issue8
Pagination746-754
Date Published2019 Aug
ISSN1931-8405
Abstract

<p>Both HIV infection and tenofovir disoproxil fumarate (TDF) treatment adversely impact bone metabolism and may lead to osteopenia, which has critical implications for youth with HIV (YWH). This study evaluates changes in the biomarkers of bone metabolism and inflammation among YWH receiving initial treatment with TDF- and non-TDF-containing antiretroviral therapies (ARTs). YWH [ = 23, median age 21 years (range 18-24), 87% male, 61% African American] were assessed for inflammatory and bone metabolism biomarkers at enrollment, after 48 weeks of TDF-containing ART, and 96 weeks of ART without TDF with continued viral suppression. Spearman's rank correlation evaluated biomarker associations. Bone alkaline phosphatase, parathyroid hormone, and osteopontin increased after TDF treatment. All fell after TDF was discontinued. Levels of RANKL and osteoprotegerin did not change throughout the study. There was little correlation between biomarkers of bone metabolism and either macrophage or lymphocyte activation at any time point. Our results establish baseline associations between bone metabolism and immune biomarkers for this population, and find that before CD4 T cell decline chronic inflammation does not perturb biomarkers of bone metabolism among YWH. The adverse effects of TDF on bone health may be marginal for YWH at the early stages of disease.</p>

DOI10.1089/AID.2018.0270
Alternate JournalAIDS Res. Hum. Retroviruses
PubMed ID31115244
PubMed Central IDPMC6688113
Grant ListU01 HD040533 / HD / NICHD NIH HHS / United States
T32 AI007062 / AI / NIAID NIH HHS / United States
U01 HD040474 / HD / NICHD NIH HHS / United States
UL1 RR025780 / RR / NCRR NIH HHS / United States
U01 AI068632 / AI / NIAID NIH HHS / United States
UL1 RR024131 / RR / NCRR NIH HHS / United States
U01 DA044571 / DA / NIDA NIH HHS / United States
M01 RR010284 / RR / NCRR NIH HHS / United States
P30 AI064518 / AI / NIAID NIH HHS / United States
UL1 RR024134 / RR / NCRR NIH HHS / United States
M01 RR020359 / RR / NCRR NIH HHS / United States